SCHEMBL23770751

SCHEMBL23770751

Cc1ccc(C(F)(F)F)cc1-c1nc(NSc2cccc(N3CCN(C(=O)OC(C)(C)C)CC3)n2)ccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.40
SYK P43405 1/20 0.38
SUV39H2 Q9H5I1 4/20 0.38
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
KIF18A Q8NI77 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
MAPT P10636 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
MCL1 Q07820 1/20 0.36
CCNK O75909 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCND3 P30281 1/20 0.36
CDK9 P50750 1/20 0.36
CDK6 Q00534 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770446 0.91 SUV39H2 (0.39) GPR119SUV39H2KIF18AMEN1KMT2A
SCHEMBL19925728 0.84 MCL1 (0.42) GPR119SYKSUV39H2RAF1BRAF
SCHEMBL29464503 0.84 MCL1 (0.42) GPR119SYKSUV39H2RAF1BRAF
SCHEMBL23770697 0.83 CKS1B (0.41) GPR119KIF18ACKS1BSKP1SKP2
SCHEMBL23770486 0.82 ABL1 (0.33) RAF1BRAF
SCHEMBL23770612 0.77 GPR119 (0.41) GPR119KIF18ACKS1BSKP1SKP2
SCHEMBL23770707 0.76 AGPAT2 (0.39) BRAFMAPTMCL1
SCHEMBL19925051 0.75 BRD4 (0.41) SUV39H2KIF18AMEN1KMT2ACKS1B
SCHEMBL29464405 0.75 BRD4 (0.41) SUV39H2KIF18AMEN1KMT2ACKS1B
SCHEMBL23748047 0.75 TRPV1 (0.38) RAF1BRAFKMT2AMAPTTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed